%0 Journal Article %A Alessio Imperiale %A Caroline Boursier %A Nicolas Sahakian %A Eric Ouvrard %A Elodie Chevalier %A Frédéric Sebag %A Pietro Addeo %A David Taïeb %T Values of 68Ga-DOTATOC and Carbidopa-assisted 18F-DOPA PET/CT for insulinoma localization %D 2021 %R 10.2967/jnumed.121.262401 %J Journal of Nuclear Medicine %P jnumed.121.262401 %X To assess the value of 68Ga-DOTATOC and carbidopa-assisted 18F-DOPA in 21 hypoglycaemic patients. Methods: All patients who underwent 68Ga-DOTATOC and/or carbidopa-assisted 18F-DOPA PET/CT for suspicion of insulinoma from January 2019 to January 2021 were retrospectively analysed. Insulinoma final diagnosis was defined according to pathological reports or consensus. Results: During the study period, 21 patients underwent both 68Ga-DOTATOC and 18F-DOPA PET/CT. A final diagnosis of insulin-secreting tumour was reached in 12 cases, including 11 insulinomas and 1 small mixed neuroendocrine/non-neuroendocrine neoplasm. 18F-DOPA and 68Ga-DOTATOC PET/CT were positive in 5 (45%) and 7 (64%) of 11 cases, respectively, with 4 concordant positive findings. Moreover, 1 insulinoma was visualized exclusively by 18F-DOPA PET/CT and 3 by 68Ga-DOTATOC PET/CT only. 18F-DOPA and 68Ga-DOTATOC PET/CT were falsely positive in 1 non-functioning pancreatic neuroendocrine tumour. Conclusion: When 68Ga-exendin-4 is not available, 68Ga-SSTR PET/CT should be the first choice for insulinoma functional imaging. %U https://jnm.snmjournals.org/content/jnumed/early/2021/07/16/jnumed.121.262401.full.pdf